EMERGENT BIOSOLUTIONS INC. Proceeds from Sales of Assets, Investing Activities
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Sales of Assets, Investing Activities of $0 for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSalesOfAssetsInvestingActivities · last filed 2013-11-08
- EMERGENT BIOSOLUTIONS INC. proceeds from sales of assets, investing activities for the quarter ending 2013-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sales of assets, investing activities for the quarter ending 2012-09-30 was $0.00.
| Period end | Proceeds from Sales of Assets, Investing Activities 3 month | Proceeds from Sales of Assets, Investing Activities 6 month | Proceeds from Sales of Assets, Investing Activities 9 month |
|---|---|---|---|
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-06 | ||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $11.77M 10-Q · filed 2013-11-08 | |
| 2012-06-30 | $11.77M 10-Q · filed 2013-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |